Edwards SAPIEN 3 TAVR Demonstrates Clinical Superiority To Surgery In PARTNER II Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Edwards SAPIEN 3 TAVR Demonstrates Clinical Superiority To Surgery In PARTNER II Study
April 4, 2016 10:33 AM EDT
Stifel reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), and raised the price target to $117.00 (from $98.00), following data presentations at American College of Cardiology. Given the outstanding data, Stifel is increasing its 2016-2020 revenue and EPS projections. On EPS, they now project 2016 at $2.67, up $0.06 from prior estimates and 2017 moves to $3.36, up $0.36 or 12% vs prior projection.
Analyst Rick Wise... More
April 4, 2016 7:35 AM EDT
BTIG upgraded Edwards Lifesciences (NYSE: EW) from Neutral to Buy with a price target of $115. The upgrade follows strong SAPIEN 3... More
April 4, 2016 6:45 AM EDT
Jefferies analyst Raj Denhoy reiterated a Buy rating and boosted his price target on Edwards Lifesciences (NYSE: EW) to $105.00 (from $100.00) after the much anticipated PARTNER II Sapien 3 data did not disappoint.
Denho commented, "Showing superiority to surgery on the primary endpoint... More
